Combination of engineered natural killer (nk) cells and antibody therapy and related methods
AssigneeIndapta Therapeutics, Inc.
InventorsAustin BIGLEY, Robert SIKORSKI, Mark W. FROHLICH
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treatment and uses involving dosing of compositions containing NK cells deficient in expression of FcRγ chain (g-NK cells) engineered with a recombinant chimeric antigen receptor (CAR) in combination with a monoclonal antibody. Among the provided methods and uses are methods and uses for treating cancer, such as multiple myeloma or lymphoma.
Claims152
A method of inducing cytolytic killing of a target cell, the method comprising contacting a target cell that is known or suspected of expressing a first antigen and a second antigen with:
- (a) a composition comprising Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), wherein the g-NK cells express a chimeric antigen receptor (CAR) comprising an extracellular binding domain that binds to the first antigen;
- and
- (b) a monoclonal antibody that binds to the second antigen.
A method of treating a cancer in a subject, the method comprising:
- (a) administering to a subject having a cancer an NK cell therapy comprising a dose of a composition comprising Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), wherein the g-NK cells express a chimeric antigen receptor (CAR) comprising an extracellular binding domain that binds to a first antigen expressed by cells of the cancer;
- and
- (b) administering to the subject a dose of a monoclonal antibody that binds to a second antigen expressed by cells of the cancer.
A method of treating a cancer in a subject, the method comprising administering to a subject having a cancer an NK cell therapy comprising a dose of a composition comprising Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), wherein:
- the g-NK cells express a chimeric antigen receptor (CAR) comprising an extracellular binding domain that binds to a first antigen expressed by cells of the cancer;
- and
- the g-NK cells express a secretable monoclonal antibody that binds to a second antigen expressed by cells of the cancer.
An engineered natural killer (NK) cell, wherein the NK cell is deficient in expression of FcRγ chain (g-NK cells), wherein the g-NK cells comprise:
- a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) comprising an extracellular binding domain that binds to the first antigen;
- and
- a heterologous nucleic acid encoding a secretable monoclonal antibody that binds to a second antigen.
Dependencies are inferred from the claim text.